This is a Phase II study to look at the effects of the investigational drug DMP 543 which has potential potent effects on platelet aggregation. This protocol consists of two parts. Part A is a dose ranging study of IIb/IIIa antagonist. Based on the findings in Part A, a second part B study will be performed using the optimum doses identified. Endpoints include tolerability and safety and also effectiveness in inhibiting platelets as assessed by platelet aggregation studies.
Showing the most recent 10 out of 1267 publications